PrintEmail
LeBoeuf Lamb

New York
+1 212 259 6420


Download VCard


Education
Columbia University Law School, 1977, J.D., Harlan Fiske Stone Scholar
Haverford College, 1971, B.A., magna cum laude, Phi Beta Kappa, History prize
University of Paris, associated with Ecole Normale Supérieure, 1974, M.A., with High Honors

Bar Admissions
New York

Stanton J. Lovenworth Partner 

Stanton J. Lovenworth has more than 30 years of experience in corporate representation, including mergers and acquisitions (M&A) and business organization. He is the global co-chair of the firm’s Information Technology and Intellectual Property Transactions Group and the firm’s Life Sciences and Healthcare practice.

Mr. Lovenworth has extensive experience in transactional intellectual property matters, including technology licensing (particularly in the pharmaceutical, biotech and software sectors); patent, merchandise, trademark and copyright licensing; protection and enforcement of trademark rights; formation of pharmaceutical, biotech, software development, telecommunications, publishing and other intellectual property-based or -centered joint ventures, collaborations and strategic alliances; and research, development, co-development, co-promotion, and supply and manufacturing agreements in the pharmaceutical and biotech sectors. In addition, Mr. Lovenworth has broad experience in mergers and acquisitions, "spin-outs" and venture capital transactions involving intellectual property assets.

For transactional intellectual property matters, representative clients include Novartis, Eli Lilly, Actavis, MedImmune, Progenics, Illumina and Advancis (pharmaceutical and biotechnology mergers and acquisitions, collaborations and licensing); Triad Financial Corporation, Rockefeller & Co., Ultimate Software and Financial Technologies International (software licensing); Omnicare and various insurance company clients (IT structuring); SONY, The Walt Disney Company and Providence Equity (entertainment industry acquisitions and divestitures); The Walt Disney Internet Group (acquisition and sale of Internet search and hosting technology); Pequot Capital, Venrock and Morgenthaler (venture capital investment in technology developers and "spin-outs"); The National Federation of Coffee Growers of Colombia and Republic of Colombia trademark protection and enforcement); Starbucks Coffee Company (trademark licensing, certification mark matters); and Unilever (integrated marketing matters). Mr. Lovenworth has been recognized in The Legal 500 US in the area of trademarks and as a New York Super Lawyer in 2006 and 2007.

Selected Activities
  • American Bar Association
  • Section of Intellectual Property
  • New York State Bar Association
  • Association of the Bar of the City of New York
  • International Trademark Association (Latin American Subcommittee on Geographical Indications)
  • Licensing Executives' Society
  • American Intellectual Property Law Association

Publications
  • "China Trade Accord May Protect Software Vendors," The National Law Journal (June 5, 1995).
  • "Protection of Well Known Trademarks in China," New York Law Journal (August 21, 1995).
  • "Planning For A New Age: Employee Ownership of Intellectual Property," The Corporate Counselor (March 1996).
  • "Exploring the Boundaries of Co-Existing Trademarks," New York Law Journal (January 15, 1999).
  • "The Third Thing: Defining Trade Dress After Wal-Mart v. Samara Brothers," Legal Times (March 4, 2002).
  • "Merck v. Integra: Its effect on Innovative Drug Discovery," Bio-IT World (August 2, 2005).
  • "The Research Tool Conundrum," New York Law Journal (October 17, 2005).
  • "Welcome to the World of Wiki and Linux: Enforcement of Copyright in Collaborative Works," TMCnet (September 27, 2006).
  • "Exit via the Pipeline: M&A Activity in the Pharmabiotech Sector," Daily Deal (November 28, 2006).
  • "Protecting Geographically Unique Products", New York Law Journal (January 22, 2008).

Speeches and Programs
  • BioBusiness 2004, "When Equity Enters the Equation: Examining the Key Governance and Alliance Issues in Pharma/Biotech Deals" (Geneva, January 28, 2004).
  • New York Biotechnology Association, "What You Should Know About Your Fiduciary Duties to Your Partners" (New York, May 25, 2005).
  • ACI, "Life Sciences IP Due Diligence" (New York, January 31 and June 27, 2006).
  • New York Biotechnology Association, "Biotech-Pharma Collaborations: The Fiduciary Duties You Owe to Your Collaboration Partners and How to Handle Them" (New York, April 18, 2006).
  • Licensing Executives Society, "Commercial and Ethical Issues in Pandemic Flu Collaboration" (New York, September 13, 2006).
  • BioNetwork 2006, "Creative New Deal Structures" (Laguna Beach, October 4, 2006).
  • ACI, "Using Due Diligence to Identify and Minimize Risks" (New York, November 14, 2006).